Lidocaine attenuates CFA‑induced inflammatory pain in rats by regulating the MAPK/ERK/NF‑κB signaling pathway
- Shuli Zhang
- Yan Li
- Yingjun Tu
Affiliations: Department of Pain Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Department of Gynecology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Department of Orthopaedics, Yili Friendship Hospital, Yining, Xinjiang 835000, P.R. China
- Published online on: January 14, 2021 https://doi.org/10.3892/etm.2021.9643
Copyright: © Zhang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Lidocaine is a commonly used local anesthetic that also confers analgesic effects, resistance to hyperalgesia and anti‑inflammatory properties. The present study aimed to explore the effects of lidocaine on complete Freund's adjuvant (CFA)‑induced inflammatory pain. In the present study, rats were subcutaneously injected with CFA to investigate the molecular mechanisms associated with lidocaine in an inflammation‑induced pain model. Firstly, CFA was subcutaneously injected into the paws of Sprague‑Dawley rats, following which lidocaine or saline and the ERK agonist recombinant human epidermal growth factor (rh‑EGF) were injected via the tail vein. Rat behavior was then assessed at 0 and 4 h, 1, 4, 7 and 14 days after CFA treatment. Proinflammatory cytokine levels in the serum were measured using ELISA. Western blotting was performed to detect the protein levels of phosphorylated (p)‑ERK1/2, ERK1/2 and NF‑κB subunits p‑p65 and p65. Reverse transcription‑quantitative PCR was used to measure the mRNA expression of ERK1/2 and p65 in rat spinal cord tissues. The results showed that injection of CFA significantly reduced the mechanical withdrawal threshold, thermal withdrawal latency and the frequency of responses to cold stimulation in rats, whilst promoting tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6 levels in addition to ERK1/2, p65 protein phosphorylation. These effects were alleviated by lidocaine treatment. Furthermore, treatment with rh‑EGF reversed the protective effects of lidocaine on inflammatory pain caused by CFA. In conclusion, lidocaine inhibits the inﬂammatory response and pain through the MAPK/ERK/NF‑κB pathway in a rat model of pain induced by CFA.